BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Quarterly Earnings Results, Misses Estimates By $3.04 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) released its quarterly earnings results on Wednesday. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04), FiscalAI reports. BioCryst Pharmaceuticals had a negative return on equity of 91.42% and a negative net margin of 51.71%.The firm had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. During the same quarter in the prior year, the company posted $0.20 EPS. The firm’s revenue was up 7.5% on a year-over-year basis.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• Strong commercial momentum: ORLADEYO net revenue was $148.3 million in Q1, with monthly new patient prescriptions slightly ahead of 2025 averages and early pediatric launch demand observed across all four pellet strengths.
• A manufacturing issue with ORLADEYO pediatric pellets will delay initial product fulfillment; the company says it does not expect the delay to change 2026 revenue guidance and will provide more timing details later this quarter.
• Development progress for navenibart is ahead of plan: ALPHA-ORBIT pivotal enrollment should complete by end of next month at ~145 patients, keeping a U.S. filing target by the end of 2027 and supporting a sizable injectable opportunity.
• Pipeline expansion: BCX17725 (KLK5 inhibitor) has started dosing in Part 4 of Phase I (up to 12 patients) with proof-of-concept data expected by year-end for Netherton syndrome.
• Mixed financial picture: GAAP was impacted by an in-process R&D charge of $698 million from the Astria asset acquisition, while non-GAAP results show strong operating profitability and pro forma liquidity of roughly $331 million after a $70 million upfront European license and a $400 million credit facility.

BioCryst Pharmaceuticals Stock Down 0.2%

BCRX traded down $0.02 during trading on Friday, reaching $8.88. The stock had a trading volume of 714,109 shares, compared to its average volume of 5,054,184. The stock has a 50 day moving average of $9.08 and a two-hundred day moving average of $7.83. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -4.98 and a beta of 0.57. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31.

Insider Activity

In other news, insider Alane P. Barnes sold 150,000 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $9.15, for a total value of $1,372,500.00. Following the sale, the insider owned 400,703 shares of the company’s stock, valued at approximately $3,666,432.45. The trade was a 27.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Focus Partners Wealth acquired a new position in BioCryst Pharmaceuticals during the third quarter worth about $77,000. Elevation Point Wealth Partners LLC bought a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at about $81,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of BioCryst Pharmaceuticals in the 3rd quarter worth approximately $81,000. Cetera Investment Advisers raised its holdings in shares of BioCryst Pharmaceuticals by 13.8% in the 4th quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 1,494 shares in the last quarter. Finally, Quantessence Capital LLC acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $103,000. Institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BCRX. Wedbush reduced their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday. Evercore began coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price target on the stock. Weiss Ratings raised BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Needham & Company LLC reduced their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Royal Bank Of Canada decreased their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.70.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.